1.9 losers clubbin in, goodness. |
Oligarchs have financed Trump property empire probably backed by a guarantee from the orange manchild
Just needs a phone call |
Stranger things have happened but i think our CEO will be making good use of her extensive contact lists over the pond ! |
Bbd ...lol. Trump , what a w anchor. The share price has responded well..All will be revealed soon. Reverse takeover by N4P ...lol, lol, lol. TimeLord alert. |
Don’t get me started on Trump except to say that the Ruskies must have something very big on him!! lol
I have a feeling that the new CFO is working on something as we speak. Hell of a risk to be short at this point but then shorting sheep will be sheep especially when they are a little overweight. |
Belgium unit sale probably inked too. |
SP flying on zero news. Wonder if they.ve flogged something else? Either way, a great recovery. Tis what is. Geez, they might have some predator around ...unsure why that would happen BCOS in another 6 months will be trading at 20p ISH. Odd share price action. MMs getting share price artificially high for fwd selling play. Wouldn't surprise me. Bent as ... |
Excellent shorting opportunity. Prepare for a deeply discounted placing. |
Another example today of which market AVCT are now targeting. Smart move imo |
"Following the divestment of Launch Diagnostics, the Company's cash runway will extend into Q1 2026."
Which will be just after they finally complete Phase 1 and publish the data (allegedly). What then another £50 m pay day loan or a placing? |
So have a got this right, Avacta paid £29,201 m to acquire Launch Diagnostics, a Belgium based company and sells it just over 2 years later for £12.91 m back to a Belgium company, a master piece of corporate activity that! |
bbd2,
"Nice. I certainly wouldn’t want to be short"
Why? What do you know about shorting? Have you ever shorted anything ever in your entire life?
Did you read the bit in the RNS that says:
"Following the divestment of Launch Diagnostics, the Company's cash runway will extend into Q1 2026."
What do you think happens in Q1 2026? It's less than a year away!
Did you read anything in either RNS about "Phase 2 trials" and how much they might cost?
No, because there wasn't anything in there about Phase 2! They still haven't finished the Phase 1 trial!
How much cash do you think that they need to run a Phase 2 trial? How about Phase 3?
FFS you're 100% focused on completely the wrong things!
JakNife |
Nice. I certainly wouldn’t want to be short |
RNS arriving like buses!!
Avacta Announces Promising Early Efficacy and Safety Data for AVA6000 in the Phase 1a Dose Escalation and Ongoing Enrollment in the Phase 1b Expansion Cohorts
Encouraging Progression Free Survival (PFS) data observed in patients with salivary gland cancers compared to conventional treatments |
Well they sold the only decent bit of Avacta that actually makes money while the rest of it burns shareholder funds consistently. I am not the one holding this dog share
Where is myles mcnulty? |
 LONDON AND PHILADELPHIA - 07 March 2025 - Avacta Therapeutics (AIM: AVCT, 'the Company'), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, announces that it has agreed to sell Launch Diagnostics Holdings Limited ("Launch Diagnostics") and its subsidiaries, its UK-based and largest diagnostics unit, for £12.9 million in cash to Duomed Belgium NV, a subsidiary of Palex Healthcare Group S.L.U. Completion of the sale is expected by the end of April 2025, subject to customary closing conditions. The sale proceeds will be used to further Avacta's pre|CISION® platform.
This disposal is a significant step towards delivering a key Board objective of the Company becoming a pure-play biotechnology company. In order to complete the divestment of its diagnostics business operations, Avacta is also in discussions regarding the sale of its remaining and much smaller Belgian-headquartered diagnostics unit, Coris BioConcept SRL.
Launch Diagnostics delivered audited revenues of £17.9 million and profit after tax of £0.38 million in the year ended 31 December 2023 and has traded in line with the Board's expectations during the year ended 31 December 2024. As at 30 June 2024 Launch Diagnostics had unaudited net assets of £13.65 million.
Following the divestment of Launch Diagnostics, the Company's cash runway will extend into Q1 2026 |
What are you suggesting they shouldn't have sold it to extend the cash runway for their drug development. Dope |
Selling assets at a loss just to extend the cash runway, and another sign of management poor delivery which they openly admit. I agree with next stop 20p tbh. Where is that 'guru' myles mcnulty |
Register for real-time alerts, custom portfolio, and market movers
Hot Features
Premium
